NASDAQ:VRTX Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis $472.27 -4.68 (-0.98%) Closing price 04:00 PM EasternExtended Trading$477.42 +5.16 (+1.09%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Vertex Pharmaceuticals Stock (NASDAQ:VRTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vertex Pharmaceuticals alerts:Sign Up Key Stats Today's Range$472.03▼$480.0050-Day Range$434.03▼$479.5352-Week Range$377.85▼$519.88Volume907,904 shsAverage Volume1.09 million shsMarket Capitalization$121.28 billionP/E RatioN/ADividend YieldN/APrice Target$512.30Consensus RatingModerate Buy Company Overview Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Read More Vertex Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreVRTX MarketRank™: Vertex Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 127th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingVertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.52, and is based on 12 buy ratings, 14 hold ratings, and no sell ratings.Amount of Analyst CoverageVertex Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vertex Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth12.03% Earnings GrowthEarnings for Vertex Pharmaceuticals are expected to grow by 12.03% in the coming year, from $15.63 to $17.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vertex Pharmaceuticals is -120.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vertex Pharmaceuticals is -120.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVertex Pharmaceuticals has a P/B Ratio of 7.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vertex Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.50% of the float of Vertex Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVertex Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vertex Pharmaceuticals has recently decreased by 97.60%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVertex Pharmaceuticals does not currently pay a dividend.Dividend GrowthVertex Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-3.12 Percentage of Shares Shorted1.50% of the float of Vertex Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVertex Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vertex Pharmaceuticals has recently decreased by 97.60%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.26 News SentimentVertex Pharmaceuticals has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 40 news articles for Vertex Pharmaceuticals this week, compared to 31 articles on an average week.Search Interest37 people have searched for VRTX on MarketBeat in the last 30 days. This is an increase of 68% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -12% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,084.00 in company stock.Percentage Held by InsidersOnly 0.20% of the stock of Vertex Pharmaceuticals is held by insiders.Percentage Held by Institutions90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vertex Pharmaceuticals' insider trading history. Receive VRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VRTX Stock News HeadlinesVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives $511.71 Average PT from AnalystsJuly 23 at 4:17 AM | americanbankingnews.comVertex Pharmaceuticals' (VRTX) ALYFTREK Gains Approval in Canada | VRTX Stock NewsJuly 22 at 1:46 PM | gurufocus.comGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthright” — a $150 trillion wealth vault that’s remained untouched for over a century. Jim Rickards believes President Trump is about to unleash it — and investors who move first could come out on top. The full story is now available.July 24 at 2:00 AM | Paradigm Press (Ad)3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial ResultsJuly 22 at 4:14 AM | fool.comVertex Pharmaceuticals: Hold Rating Amid Uncertainty in VX-993 Trial OutcomesJuly 21 at 4:44 PM | tipranks.com3 Top Growth Stocks to Buy in the Second Half of 2025July 19, 2025 | fool.comWhat is William Blair's Forecast for VRTX FY2025 Earnings?July 17, 2025 | americanbankingnews.comVertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $517.00July 16, 2025 | americanbankingnews.comSee More Headlines VRTX Stock Analysis - Frequently Asked Questions How have VRTX shares performed this year? Vertex Pharmaceuticals' stock was trading at $402.70 at the start of the year. Since then, VRTX stock has increased by 17.3% and is now trading at $472.27. How were Vertex Pharmaceuticals' earnings last quarter? Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its quarterly earnings data on Monday, May, 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by $0.23. Vertex Pharmaceuticals's revenue was up 2.6% compared to the same quarter last year. Read the conference call transcript. Does Vertex Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Vertex Pharmaceuticals: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others. Who are Vertex Pharmaceuticals' major shareholders? Top institutional shareholders of Vertex Pharmaceuticals include Robeco Institutional Asset Management B.V. (0.13%), Aberdeen Group plc (0.11%), Swedbank AB (0.10%) and Assenagon Asset Management S.A. (0.09%). Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Charles F Wagner Jr, Bruce I Sachs, Bastiano Sanna, David Altshuler, Carmen Bozic, Edward Morrow Atkinson III, Jonathan Biller, Jeffrey M Leiden, Kristen Ambrose, Joy Liu, Sangeeta N Bhatia and Yuchun Lee. View institutional ownership trends. How do I buy shares of Vertex Pharmaceuticals? Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vertex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), QUALCOMM (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings5/05/2025Today7/24/2025Next Earnings (Confirmed)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:VRTX CIK875320 Webwww.vrtx.com Phone(617) 341-6100Fax617-576-2109Employees6,100Year Founded1989Price Target and Rating Average Price Target for Vertex Pharmaceuticals$512.30 High Price Target$586.00 Low Price Target$420.00 Potential Upside/Downside+8.5%Consensus RatingModerate Buy Rating Score (0-4)2.52 Research Coverage27 Analysts Profitability EPS (Trailing Twelve Months)($3.92) Trailing P/E RatioN/A Forward P/E Ratio30.22 P/E GrowthN/ANet Income-$535.60 million Net Margins-8.91% Pretax Margin-2.70% Return on Equity-3.36% Return on Assets-2.42% Debt Debt-to-Equity Ratio0.01 Current Ratio2.65 Quick Ratio2.29 Sales & Book Value Annual Sales$11.02 billion Price / Sales11.01 Cash FlowN/A Price / Cash FlowN/A Book Value$63.72 per share Price / Book7.41Miscellaneous Outstanding Shares256,800,000Free Float256,283,000Market Cap$121.28 billion OptionableOptionable Beta0.41 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:VRTX) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.